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Abstract Hypersensitivity to nonsteroidal anti-inflammatory
drugs (NSAIDs) associated with chronic rhinosinusitis (CRS)
and/or asthma comprises a distinct clinical syndrome referred
to as NSAIDs exacerbated respiratory disease (NERD). Pa-
tients with NERD tend to have more severe course of both
upper (CRS and nasal polyps) and lower airway (asthma)
diseases and are usually recalcitrant to conventional treatment
modalities. Diagnosing and phenotyping of patients with
NERD are critical for prevention of drug-induced adverse
reactions and open novel options for management of underly-
ing chronic airway inflammatory diseases. Diagnosis of
NERD is based on detailed clinical history confirmed by chal-
lenge with aspirin, but new diagnostic approaches are current-
ly being developed. This review article focuses on the diag-
nostic approach to a patient with CRS and hypersensitivity to
NSAIDs, emphasizing the importance of diagnosis for proper
patient’s management.
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Introduction
Acute forms of hypersensitivity to aspirin and other nonste-
roidal anti-inflammatory drugs (NSAIDs) are among the most
common drug hypersensitivities, may affect 1–2 % of general
population and manifest with the whole variety of symptoms
involving skin (rush, urticaria, and angioedema), respiratory
tract (rhinorrhea, nasal congestion, and bronchospasm), and in
some patients systemic anaphylaxis may develop [1, 2•].
Among patients with asthma and/or chronic rhinosinusitis
(CRS) with nasal polyps, the prevalence of NSAIDs hyper-
sensitivity is significantly higher reaching 26 % and is associ-
ated with severe eosinophilic hyperplastic inflammation of
both upper and lower airway mucosa [3]. This syndrome has
been previously referred to as Baspirin triad^, andmore recent-
ly, the term NSAIDs-exacerbated respiratory disease (NERD)
has been used, reflecting the presence of chronic inflammation
of upper and lower mucosa of patients with this type of drug
hypersensitivity [4•].
Chronic Rhinosinusitis and NSAID-Hypersensitivity
History of hypersensitivity to aspirin and other NSAIDs is a
hallmark of particularly persistent and resistant to treatment
form of rhinosinusitis, associated with recurrent nasal
polyposis [5–8] (Fig. 1). Although NSAIDs can evoke hyper-
sensitivity reactions in patients with CRS, but without lower
airway involvement, the majority of patients would suffer
from chronic bronchial asthma. The higher than usual severity
of the upper airway disease in NERD patients is reflected by
recurrence of nasal polyps and frequent need for sinus surgery
[7, 9]. As it has been documented with computer tomography
in these patients, mucosal hypertrophy usually involves all
sinuses and nasal passages and has significantly higher extent
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Pathophysiology of NERD should be considered as a coinci-
dence of two possibly distinctive, but to some extent overlap-
ping mechanism: one being responsible for NSAIDs-induced
acute hypersensitivity reaction and the other determining the
presence of chronic eosinophilic mucosal inflammation in the
airways, and resulting in persistent symptoms of
rhinosinusitis, nasal polyps, and asthma [11].
Mechanism of Acute NSAIDs-Induced Hypersensitivity
Reactions
Hypersensitivity reaction induced by aspirin and NSAIDs is
not immunological phenomenon, but results from inhibition
of cyclooxygenase-1 and prostaglandin synthesis, which leads
to activation of inflammatory cells (mostly mast cells and
eosinophils, but possibly platelets) with subsequent release
of leukotrienes and other inflammatory mediators in the mu-
cosa [12–14]. These mediators are responsible for clinical
manifestation of acute hypersensitivity reaction: bronchial ob-
struction, rhinorrhea, and nasal congestion. Avoiding aspirin
and other NSAIDs with strong anti-COX-1 activity or using
selective COX-2 inhibitors would prevent development of
acute reactions. Although the causal relationship between in-
hibition of COX-1 by NSAIDs and development of symptoms
has been well documented, the mechanism of inflammatory
cells activation by NSAIDs is speculative and potentially may
involve increased susceptibility of cyclooxygenase-1 to
inhibition by NSAIDs, intrinsic deficiency of prostaglandin
E2 [15•], and/or decreased function of prostaglandin E2 [16,
17]. Cysteinyl leukotrienes (LTC4/D4) are consistently in-
creased after positive aspirin challenge in lower and upper
airways, and leukotriene LT1 receptor antagonists partially
prevent NSAID-induced reaction suggesting a key role of leu-
kotrienes in the pathophysiology of acute NSAIDs-induced
reaction [18]. The role of other arachidonic acid metabolites
as prostaglandin D2 (PGD2) or 15-hydroxyeicosatetraenoic
acid (15-HETE) is also feasible [19–22, 23•].
Pathomechanism of Chronic Eosinophilic Airway
Inflammation
Increased tissue eosinophilia and release of eosinophil cation-
ic protein (ECP) in nasal polyps from NERD patients have
been linked to distinctive profile of cytokine expression and
upregulation of cytokines related to eosinophil activation and
survival (e.g., IL-5, GM-CSF, RANTES, and eotaxin) [16, 24,
25] and is associated with differential expression of remodel-
ing markers [26]. It has been recently documented that higher
INF-γ levels are produced by eosinophils in nasal polyps tis-
sue from NERD patients and INF-γ promoted maturation of
eosinophil progenitors, results in enhanced expression of
eosinophil-associated genes related to the leukotriene path-
ways (e.g., CysLT1 receptor or LTC4 synthase) [27].
Mast cells seem to be important component of the upper
and lower airway inflammation in NSAIDs-hypersensitive pa-
tients [28, 29], since serum baseline levels of mast cell derived
mediators tryptase and stable PGD2 metabolite are elevated
[30]. In the nasal polyp tissue, the density of mast cells (and
stem cell factor) was correlated with the number of
polypectomies, implicating an important role for these cells
in the pathogenesis of nasal polyposis [28].
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• More difficult to control
• Increased death risk
Aspirin/NSAID triad
Fig. 1 Clinical characteristics of
NSAID exacerbated respiratory
disease (modified from M.L
.Kowalski, S. Bavbek, Aspirin
Exacerbated Respiratory Disease,
in Global Atlas of Asthma, Eds.
C.A. Akdis, I. Agache, pp 92-94,
EAACI 2013)
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Several abnormalities related to both cyclooxygenase and
lipoxygenase pathways of arachidonic acid (AA) metabo-
lism have been documented in the upper airway mucosa of
NERD patients [31, 32]. Decreased expression of COX-2
mRNA leading to lower generation of PGE2 by nasal polyps,
nasal polyp epithelial cells, and bronchial fibroblasts was
reported [33–36] which together with reduced expression
of prostaglandin EP2 receptors could result in impaired
anti-inflammatory response [37, 38]. An increased genera-
tion of cysteinyl leukotrienes, overexpression of enzymes
involved in production of leukotrienes (5-lipoxygenase and
leukotriene C4 synthase) together with increased expression
of leukotriene type 1 (LT1) receptors in the nasal mucosa of
NERD patients may result in local hyperresponsiveness to
leukotrienes in this subpopulation of patients [39, 40]. On
the other hand, chronic treatment with LT1 receptor antago-
nist is not more effective in relieving nasal and bronchial
symptoms or reducing polyp size in NERD as compared to
NSAID-tolerant patients, thus other factors had to be in-
volved in the persistence of inflammation in these patients
[41, 42]. A decreased production of the anti-inflammatory
lipoxin A4 in nasal polyp tissue and peripheral blood leuko-
cytes from NSAID-sensitive patients further suggests an im-
portant role for dysregulation of AA metabolism [39, 40].
However, in patients with NERD eosinophilic inflammation
in the lower and upper airways may precede, even several
years, development of hypersensitivity to aspirin and persists
even if they avoid intake of aspirin or other NSAIDs,
pointing at involvement of other factors and mechanism,
beyond AA metabolism [43].
The role for infections, both viral and bacterial, has been
postulated, but not convincingly documented [44]. Higher
concentrations of IgE-antibodies to Staphylococcal aureus en-
terotoxins (SAEs) in nasal polyps and serum have been asso-
ciated with the presence of NSAIDs hypersensitivity, suggest-
ing that Staphylococcus aureus superantigens may trigger T
cell-mediated inflammatory reaction and/or exert direct effects
on eosinophil proliferation and survival in the airway mucosa
of NERD patients [45, 46]. Genetic background may be also
important factor determining different pathophysiology and
higher severity of CRS in NSAIDs hypersensitive patients
[47].
Diagnostic Approach to a Patient with NERD
Patients suspected to have NERD require not only documen-
tation of an acute hypersensitivity reaction (by history and/or
aspirin challenge) but also detailed evaluation of the extent of
underlying diseases of the upper and lower airways (Fig. 2).
Diagnosis of Chronic Rhinosinusitis
Diagnosis of CRS is based on history of presence of typical
sinonasal symptoms (nasal blockage or obstruction, nasal dis-
charge, and olfactory dysfunction) for more than 12 weeks
and should be supported by nasal endoscopy and computed
tomography (CT) scan of paranasal sinuses [48, 49]. Patients
with NSAIDs hypersensitivity on average would have a his-
tory of long-lasting CRS with higher than average severity
Skin testing with culpit drug is not
recommended
Ask about clinical pattern















In vitro test : BAT, CAST, ELISA with
culprit drug are not validated
Perform oral, bronchial or




Fig. 2 Diagnostic steps in a
patient with chronic rhinosinusitis
and suspected hypersensitivity to
NSAIDs
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and resistance to both pharmacological and surgical treatment
[7]. Reduced or lost sense of smell which commonly occurs in
CRS patients with nasal polyps with and without NSAIDs
hypersensitivity may be a leading symptom in NERD patients
[50].
A distinctive feature of CRS in NERD patients is rapid
recurrence of nasal polyps and mucosal hypertrophy follow-
ing standard polypectomy or even functional endoscopic sinus
surgery (FESS) [9]. It has been documented that patients with
NERD have ten times increased risk of polyp recurrence after
FESS as compared to aspirin tolerant patients [48, 49].
On CT scans, almost all patients with NERD have mucosal
hypertrophy, and its extent is significantly higher in NSAIDs-
hypersensitive as compared to NSAIDs-tolerant patients [10].
The intensity of sinus hypertrophy assessed by CT may pre-
dicts probability of NERD, and sinus CT score below 12
would support the likelihood of aspirin tolerance in a patients
with unclear history of hypersensitivity reaction to aspirin and
NSAIDs [48].
Comorbidities
Only a tiny fraction of patients with CRS and nasal polyps is
reacting to aspirin and NSAIDs only with upper respiratory
symptoms, and even those with time will present lower symp-
toms after NSAIDs. Large majority will have a history of
lower airway symptoms (dyspnea and wheezing) after aspirin
intake, and these patients usually suffer from chronic bronchi-
al asthma [51]. Patients with NERD tend to suffer from more
severe form of the disease which is associated with less con-
trol and with increased risk of life-threatening asthma attacks
[8, 2•].
All patients with nasal polyps and NSAIDs hypersensitiv-
ity should also undergo full allergic evaluation since majority
(50–70 %) may have allergic sensitizations to inhalant aller-
gens; thus, atopy should not exclude the suspicion of NSAIDs
hypersensitivity if other risk factors (e.g., severe asthma or
nasal polyposis) exist [52–55]. The presence of atopy was
suggested to be a risk factor for aspirin hypersensitivity
among asthmatics patients challenged with oral aspirin, thus
atopic sensitization to inhalant allergens may be important
mechanism contributing to the pathogenesis of the airway
inflammation in a patient with NERD [53].
Diagnosis of NSAIDs Hypersensitivity
History and Physical Examination
Patient with NERD would present a history of acute
rhinorrhea and nasal congestion usually accompanied by
bronchial symptoms (dyspnea), which develop usually within
1–2 h after ingestion of aspirin or other NSAIDs (e.g.,
naproxen, diclofenac, or ketoprofen) with known COX-1 in-
hibitory capacity. On the other hand patient usually reports,
that some NSAIDs, which are weak inhibitors of prostaglan-
din synthesis, like paracetamol and preferential COX-2 inhib-
itors, are well tolerated.
Approximately 10 % of patients with NERD may simulta-
neously manifest non-respiratory, usually cutaneous symp-
toms (urticaria and/or angioedema) after intake of aspirin.
Thus, a patient with CRS and history of adverse reaction to
aspirin or other NSAIDs should be fully evaluated with re-
spect to potential type of hypersensitivity which may involve
in addition lower respiratory and cutaneous symptoms [2•].
Provocations Tests
Although in clinical practice diagnosis of drug hypersensitiv-
ity is usually based on history of adverse reaction associated
with the culprit drug, such history may not be reliable leading
to either under diagnosis or over diagnosis of drug hypersen-
sitivity [56•]. In study of Dursun et al. [57], history of NSAIDs
-induced reactions could not be confirmed with oral chal-
lenge in 16 % of patients with NERD, and only 43 % patients
with chronic sinusitis, nasal polyps, and asthma who were
avoiding aspirin or NSAIDs had a positive oral aspirin prov-
ocation. Thus, oral aspirin challenge is recommended to con-
firm the diagnosis of NSAIDs hypersensitivity regardless of
the clinical manifestation, while nasal or bronchial provoca-
tion with lysine-ASA may be alternatively used in patients
with respiratory symptoms [58, 59].
Advantages and limitations of various provocation
methods are summarized in Fig. 3.
Oral Provocation Test
Several protocols for oral aspirin provocation varying in rec-
ommended aspirin dose increments and intervals between up
dosing are available, and recently, EAACI/GA2LEN expert
panel proposed a protocol which merges experience of several
groups [58, 60–62].
Oral challenge should be performed in a setting with im-
mediate access to emergency equipment, and service after all
contraindications were considered [63]. In patients with asth-
ma, the disease should be well controlled and FEV1 should
exceed 70 % of predicted values. On the first day, in order to
establish baseline variability, placebo capsules are adminis-
tered every 1.5–2 h and FEV1 is measured every 30 min (re-
spiratory function is monitored even if in patients without
history of asthma). On the second day, patient receives initial-
ly 10–30 mg of aspirin and the dose is doubled in 1.5 to 3 h
intervals until positive reaction occurs. In a patient with
rhinosinusitis, without bronchial asthma, development of up-
per respiratory symptoms (nasal congestion and rhinorrhea)
may be diagnostic. Acoustic rhinomanometry can be used to
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document nasal obstruction during the challenge. In a patient
with asthma, the reaction is considered positive if at least 20%
fall in FEV1 occurs, which may be accompanied nasal, ocular,
cutaneous, or gastrointestinal symptoms. If the final dose
312 mg of aspirin (corresponding to 500 mg of cumulative
dose) is ingested and well tolerated the patient is considered to
be aspirin tolerant [63].
The negative challenge result should be analyzed with cau-
tion since it may reflect either development of “silent desen-
sitization” during the challenge procedure or blocking effects
of medications used to control chronic inflammatory disease
[64, 65]. For example, the use of antihistamines may signifi-
cantly decrease development not only of cutaneous but also
respiratory symptoms. On the other hand, discontinuing con-
troller medications before aspirin challenge in patients with
suspected NSAIDs hypersensitivity is not recommended since
it may increase the risk of severe reactions [66, 67].
Since diagnostic oral challenge tests are time-consuming
procedure, requiring well-experienced personnel and may be
associated with a risk of severe systemic reaction, oral provo-
cation test may be substituted with inhaled or intranasal aspi-
rin challenges [58, 68].
Nasal Provocation Test
Intranasal provocation with lysine aspirin (a soluble form of
ASA) is a good alternative for oral challenge since it is rapid,
safe, and can be performed in an outpatients setting and even
in asthmatic patients with low pulmonary function not suitable
for bronchial provocation [5, 68–72]. However, this route of
challenge cannot be used in patients with significant nasal
obstruction, turbulent nasal flow, or unspecific nasal respon-
siveness [68]. Table 1 presents studies reporting diagnostic
effectiveness of intranasal challenges with aspirin. The sensi-
tivity of aspirin nasal challenge test ranges from 38% in study
of Patriarca [72] to 87 % in study of Milewski [68] and spec-
ificity from 84 [71] to 96 % [68]. The study of Miller [73] in
which higher doses of lysine aspirin showed similar sensitivity
88 %. The nasal provocation test seems to be a safe alternative
for oral and bronchial challenge in patients with severe asthma
as in most patient intranasal delivery of aspirin did not evoke
severe bronchoconstriction [68, 74•, 75•]. However, in occa-
sional, patients application of lysine aspirin by atomizer or
using of higher doses of aspirin can lead to bronchial symp-
toms with significant drop in FEV1>30 %, which is pointing
at necessity of respiratory function monitoring by spirometry
during nasal provocation with aspirin [70, 73].
Lysine aspirin can be substituted with ketorolac another
NSAID, which in a soluble form is more easily available in
some countries [76]. Reproducibility of nasal challenges in
which combination of acoustic rhinomanometry and symp-
toms scores is used to assess the results [73, 74•, 77] is very
high reaching 98 % [73]; however, good reproducibility of
peak nasal inspiratory flow (PNIF) measurements have been
also reported [78].
Bronchial Aspirin Provocation
Bronchial provocation with lysine aspirin is reliable alterna-
tive for oral provocation with aspirin in patients with diagnosis
of asthma or with history of lower respiratory symptoms after
NSAIDs [58, 63]. However, in patients with CRS without
asthma or with history of only upper airway symptoms after
NSAID, oral provocation cannot be substituted with inhala-
tion challenge.
Advantages Limitations
Gold standard ( reliable ) Risk of severe reaction
Useful in patients with nasal
and/or bronchial symptoms
Time-consuming
Reaction easily reversible Requires special equipment
Short duration (< 4  h) Only in patients with
bronchial/nasal reaction
Reliable in patients with CRS Not possible in patients with
nasal obstruction




Fig. 3 Advantages and
limitations of oral, intranasal, and
bronchial route of aspirin
provocation in patients with
NERD (modified from M.L.
Kowalski In vivo diagnosis of
NSAIDs hypersensitivity, in
Global Atlas of Allergy, Eds C. A.
Akdis I. Agache, pp. 158-160,
EAACI, 2014)
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In Vitro Tests for Diagnosis of NSAIDs
Hypersensitivity
Although several tests based on measuring of in vitro activa-
tion of peripheral blood leukocytes have been proposed, no
in vitro test can match provocation challenges with respect to
sensitivity or specificity (Table 2).
Sulfidoleukotrienes Release Assay Aspirin-triggered re-
lease of LTC4 from peripheral blood leukocytes
(CAST-ELISA) has been tested in several studies
[79–81], in highly selected population, but has not been
validated for routine use [82–84].
Basophil Activation Tests (BAT) BATwas tested in popula-
tions of patients with both respiratory and/or cutaneous type of
hypersensitivity to different NSAIDs with not well character-
ized, control populations, and its utility for diagnosis of respi-
ratory type of aspirin sensitivity has not been sufficiently doc-
umented [75•, 85–87].
15-HETE generation assay (ASPITest) is based on obser-
vation that aspirin could more readily trigger in vitro
generation of 15-hydroxyicosatetraenoic acid (15-
HETE) from nasal polyp epithelial cells and peripheral
blood leukocytes from ASA-hypersensitive patients, as
compared to ASA-tolerant asthmatics or healthy sub-
jects, and measurement of 15-HETE release from PBLs
has been proposed to be used to confirm history of
aspirin hypersensitivity in patients with NERD [19, 20,
88]. The sensitivity of aspirin-triggered 15-HETE re-
lease (ASPITest) tested in highly selected population
of patients with NERD demonstrated 82 % sensitivity
and 83 % specificity [88]. However, more recent studies
including more heterogeneous populations of patients
with asthma and/or using isolated eosinophils demon-
strated non-specific release of 15-HETE form PBLs
and could not reproduce diagnostic performance of 15-
HETE measurement for NERD [89, 90]. Further studies
are required to refine the methodology and to assess
diagnostic effectiveness of this method.
New Diagnostic Approaches
Several biochemical abnormalities related to arachidonic acid
metabolism can be detected in easily available biological ma-
terials like blood, urine, or exhaled air of patients with NERD.
However, diagnostic value of measurement of AA metabo-
lism products to predict or confirm NSAIDs hypersensitivity
has not been assessed.
LTE4 Urinary Levels Increased basal levels of leukotriene E4
in urine have been consistently reported in NERD pa-
tients, but a significant overlap with non-sensitive
Table 2 Performance of in vitro test in the diagosis of NERD
First author Year Test No of patients Cells/stimulus Sensitivity Specificity PPV NPV
Kowalski ML 2003 AspiTest (15-HETE release) 16 Leukocytes/ 200 uM of ASA – – – –
Kowalski ML 2005 AspiTest (15-HETE release) 43 Leukocytes/ 200 uM of ASA 82 % 83 % 0.79 0.89
Kosec P 2011 AspiTest (15-HETE release) 26 leukocytes / 500uM of ASA 63 % 50 % – –
James A 2013 15-HETE release from
eosinophils upon
stimulation with ASA
7 Eosinophils / 200uM of ASA – – – –
Lebel B 2001 CAST 55 Leukocytes/beta-lactam, ASA, paracetamol
Bavbek S 2009 CAST 30 Basophils/ASA, diclophenac 25 % 92.30 % 0.29 0.91





65 % 80 % – –
Sanz ML 2005 CAST+BAT 60 Leukocytes/basophils/ASA/paracetamol/
naproxen/metamizol/diclophenac
73.30 % 71.40 % – –
Gamboa P 2004 BAT (CD63) 60 Basophils/ SA/paracetamol/naproxen/
metamizol/diclophenac
63.30 % 93.30 % – –
Sanz ML 2005 BAT 60 Basophils/paracetamol/naproxen/
metamizol/diclophenac
66.70 % 93.30 % – –
Celik G 2009 BAT (CD63) 10 Basophils 30 % 40 % –
BAT (CD203) 10 Basophils 70 % 45 %
BAT (CD69) 10 Basophils 80 % 34 %
BavbekS 2009 BAT (CD63) 18 Basophils/ASA, diclophenac 16.70 % 91.70 % – –
BAT (CD203) Basophils/ASA, diclophenac 22 % 100 % – –
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asthmatics was observed in most studies, not allowing
for using a single urine LTE4 measurement to predict
ASA-sensitivity [91–93].
Eicosanoid Profile in Exhaled Breath Condensates (EBC)
Sanak et al. proposed measuring a set of 19 eicosanoids
in EBC by complementary high-performance liquid
chromatography and/or gas chromatography–mass spec-
trometry to distinguish ASA-tolerant from ASA-
sensitive asthmatics [94]. The eicosanoid profiling in
EBC allowed for 92 % correct classification of aspirin-
intolerant subjects. The practical use of eicosanoids
measurements in EBC to diagnosis of CRS with ASA-
sensitivity is to be assessed.
Genetic Determinants of NSAIDs Hypersensitivity Several
genes have been associated with aspirin hypersensitivi-
ty—most are related to arachidonate metabolism or in-
flammatory pathways [47, 95]. HLA-DPB1*0301 allel
h a s b e en a s s o c i a t e d no t on l y w i t h a s p i r i n -
hypersensitivity but also with higher prevalence of
CRS in NERD patients [96–98]. A genome-wide asso-
ciation study documented an increased risk for develop-
ing aspirin hypersensitivity in adult patients and two
SNPs located on chromosome 6, and one of them
(rs3128965) was identified as a genetic marker for
NERD [99].
Conclusion
Hypersensitivity to aspirin and other NSAIDs is a hall-
mark of severe chronic upper and lower airway disease,
thus should be suspected and carefully diagnosed in
patients with CRS. Oral aspirin challenge remains a
gold standard for diagnosing aspirin sensitivity; howev-
er, intranasal challenge with soluble form of aspirin may
be a diagnostic alternative. Phenotyping of NERD al-
lows to recommend well-tolerated NSAID, if analgesic
and anti-inflammatory therapy is need. For some pa-
tients with confirmed hypersensitivity to NSAIDs, aspi-
rin after desensitization may be a valuable option for
management of CRS. Further work is necessary to un-
derstand the pathomechanism of this syndrome and to
improve the diagnosis of NERD.
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